Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907604 | 0.85 | ADORA2A (0.61) | ADORA2AADORA1TGFBR1 | |
| SCHEMBL29907672 | 0.76 | ADORA2A (0.51) | ADORA2AADORA1 | |
| SCHEMBL30880828 | 0.74 | SCN5A (0.47) | TGFBR1SCN5ATGFBR2 | |
| SCHEMBL29907725 | 0.73 | ADORA2A (0.54) | ADORA2AADORA1 | |
| SCHEMBL29907536 | 0.71 | ADORA2A (0.49) | ADORA2AADORA1TGFBR1TGFBR2 | |
| SCHEMBL21722347 | 0.70 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL22552066 | 0.70 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL29907760 | 0.70 | IRAK4 (0.36) | ADORA2AADORA1TGFBR1 | |
| SCHEMBL22552000 | 0.70 | ADORA2A (0.77) | ADORA2AADORA1 | |
| SCHEMBL29907696 | 0.70 | ADORA2A (0.46) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885TGFBR1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.